Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Dyslipidemia: full-pipeline trial registry
7 of 41 indexed Dyslipidemia trials are currently recruiting.
Corpus placement: #357 of 28,707 conditions by registered trial count.
41 US clinical trials · 7 currently recruiting · #357 of 28,707 conditions by registered trial count
Dyslipidemia: 41 US clinical trials tracked, 7 recruiting.
Dyslipidemia is the subject of 41 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 9 are in Phase 3-4 (later-stage) and 13 in Phase 1-2 (earlier-stage). The most active sponsor is National Heart, Lung, and Blood Institute (NHLBI), running 3 of these trials.
Enrollment posture brief
Registry condition dyslipidemia
OPEN 7 | RECR 17% | LATE 9 | EARLY 13 | RANK #357 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Carcinoma, Renal Cell (17% recruiting · 35 trials)
Dyslipidemia lists 7 open slots (17% of 41 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Dyslipidemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Dyslipidemia is recruiting below its size-band peers.
7 of 41 indexed trials (17.1%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Dyslipidemia trials is spread across many organizations.
National Heart, Lung, and Blood Institute (NHLBI) accounts for 3 of 41 trials (7.3%). 31 distinct sponsors appear on at least one study for this condition label.
-
Typical Dyslipidemia enrolment sits around 99 participants.
Median target enrolment is 99 among the 41 trials that report a genuine target (sentinel values excluded). 22 of those (53.7%) plan for fewer than 100 participants.
-
Dyslipidemia research is mostly interventional.
38 interventional and 3 observational studies make up this index (92.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
41 total, page 1 of 1
Natural History of Uncommon Dyslipidemias, Rare Lipid Disorders and Unusual Atherosclerotic Conditions
National Heart, Lung, and Blood Institute (NHLBI)
NCT06676046
Prescription of Step Counts for Targeted Changes in Body Composition and Cardiometabolic Risk in Overweight/Obese Adults
Kennesaw State University
NCT07221279
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia
AstraZeneca
NCT06980428
Cottonseed Oil Versus Matched PUFA Effects
University of Georgia
NCT06382298
Intermittent Cottonseed Oil Consumption
University of Georgia
NCT07246408
A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors
University of Connecticut
NCT07238556
Targeting Metabolic Syndrome From the Emergency Department Through Mixed-Methods: Pilot Trial
Indiana University
NCT07119658
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension
Amgen
NCT02867813
Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood
Abbott
NCT00300482
Association of Genes to Resistance to Weight Loss in Obese Patients
Interleukin Genetics
NCT00858221
Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood
AbbVie (prior sponsor, Abbott)
NCT00616772
The CREATE Wellness Study
Kaiser Permanente
NCT02302612
A Study of Physical and Metabolic Abnormalities in HIV Infected and Uninfected Children and Youth
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00069004
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
Sanofi
NCT02642159
Efficacy and Safety of Valsartan and the Combination of Valsartan and Simvastatin
Novartis
NCT00385931
Effects of Worksite Wellness Interventions on Vascular Function, Insulin Sensitivity and High-Density Lipoprotein in Overweight or Obese Women
National Heart, Lung, and Blood Institute (NHLBI)
NCT00666172
A 12-Week Study Comparing Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV-Infected Subjects
Kowa Research Institute
NCT01301066
Improving Adherence to Prescribing Guidelines for Cholesterol Lowering in Hospitalized Diabetic Patients
Washington University School of Medicine
NCT01113099
Study of Atorvastatin/Fenofibrate (LCP-AtorFen) Combination Therapy in Dyslipidemia
Veloxis Pharmaceuticals
NCT00504829
Fluvastatin in Adults With Dislipidemia With History of Muscle Problems
Novartis
NCT00125125
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 in Healthy Subjects
AstraZeneca
NCT05384262
Colesevelam Treatment for Impaired Fasting Glucose During Niacin Therapy
Radiant Research
NCT01239004
Combined Behavioral and Pharmacological Intervention for Cardiovascular Risk Reduction in Diabetic Patients
Providence VA Medical Center
NCT00357955
A Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of CAT-2003
Catabasis Pharmaceuticals
NCT01725594
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
Catabasis Pharmaceuticals
NCT01912560
Effect of a Decision Aid About Statin Use in Patients With Type 2 Diabetes Mellitus
Mayo Clinic
NCT00217061
A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C.
AstraZeneca
NCT06742853
Safety Study of BMS-770767 in Subjects With Hypercholesterolemia
Bristol-Myers Squibb
NCT01058083
Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia
Pfizer
NCT01243151
Preliminary Study of Safety and Efficacy of Policosanol
Rush University Medical Center
NCT00312923
Effect of Saturated Fat on Large Low-density Lipoprotein (LDL) and High-density Lipoprotein (HDL)
UCSF Benioff Children's Hospital Oakland
NCT00895141
Change of Fructose to Fat in South Asians
The Rogosin Institute
NCT01562782
Effects of Consuming Sugar-Sweetened Beverages With Meals for 10 Weeks
University of California, Davis
NCT01165853
Pilot Study to Evaluate the Effect of Nicotinamide Riboside on Immune Activation in Psoriasis
National Heart, Lung, and Blood Institute (NHLBI)
NCT04271735
Effects of Niacin On Fatty Acid Trapping
University of Pennsylvania
NCT01984073
ABT-335 (Choline Fenofibrate) Reverse Cholesterol Transport (RCT) Study
Radiant Research
NCT00673881
The Effect of Meal Composition on Blood Lipids
Texas Christian University
NCT02529709
Effects of Almond Intake on Atherogenic Lipoprotein Particles
UCSF Benioff Children's Hospital Oakland
NCT01792648
Fenofibrate Treatment in SCI
VA Office of Research and Development
NCT02455336
Dietary Carbohydrate Type and Cardiovascular Disease (CVD) Risk Indicators
Tufts University
NCT01610661
Development of a Novel Method to Study in Vivo Fatty Acid Metabolism Using Stable Isotope Labeled Fatty Acids in Humans
Tufts University
NCT02312492
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 6 |
| Phase 3 | 5 |
| Phase 4 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Dyslipidemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Dyslipidemia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Dyslipidemia page
41 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 7 Dyslipidemia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Heart, Lung, and Blood Institute (NHLBI) sponsors the most Dyslipidemia trials on record, review their full trial history before evaluating a specific study. See National Heart, Lung, and Blood Institute (NHLBI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Dyslipidemia condition card totals 41 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.